otlertuzumab   Click here for help

GtoPdb Ligand ID: 9951

Synonyms: CD37-SMIP [8] | TRU-016 | TRU016
Immunopharmacology Ligand
Compound class: Antibody
Comment: Otlertuzumab (TRU-016) is a monospecific, humanized anti-CD37 antibody-like protein that is being investigated as a clinical therapeutic for various form of lymphoma [4,6-7]. Otlertuzumab was developed using Aptevo's modular ADAPTIRTM platform.
1. Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, Spurgeon SE, Andritsos LA, Gopal AK, Leonard JP et al.. (2014)
A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia.
Blood, 123 (9): 1302-8. [PMID:24381226]
2. Gopal AK, Tarantolo SR, Bellam N, Green DJ, Griffin M, Feldman T, Mato AR, Eisenfeld AJ, Stromatt SC, Goy A. (2014)
Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIRâ„¢ therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients.
Invest New Drugs, 32 (6): 1213-25. [PMID:24927856]
3. Lapalombella R, Yeh YY, Wang L, Ramanunni A, Rafiq S, Jha S, Staubli J, Lucas DM, Mani R, Herman SE et al.. (2012)
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals.
Cancer Cell, 21 (5): 694-708. [PMID:22624718]
4. Pagel JM, Spurgeon SE, Byrd JC, Awan FT, Flinn IW, Lanasa MC, Eisenfeld AJ, Stromatt SC, Gopal AK. (2015)
Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR(â„¢) therapeutic protein, for relapsed or refractory NHL patients.
Br J Haematol, 168 (1): 38-45. [PMID:25146490]
5. Rafiq S, Siadak A, Butchar JP, Cheney C, Lozanski G, Jacob NK, Lapalombella R, McGourty J, Moledor M, Lowe R et al.. (2013)
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.
MAbs, 5 (5): 723-35. [PMID:23883821]
6. Robak T, Robak P. (2014)
Anti-CD37 antibodies for chronic lymphocytic leukemia.
Expert Opin Biol Ther, 14 (5): 651-61. [PMID:24555705]
7. Robak T, Robak P, Smolewski P. (2009)
TRU-016, a humanized anti-CD37 IgG fusion protein for the potential treatment of B-cell malignancies.
Curr Opin Investig Drugs, 10 (12): 1383-90. [PMID:19943209]
8. Zhao X, Lapalombella R, Joshi T, Cheney C, Gowda A, Hayden-Ledbetter MS, Baum PR, Lin TS, Jarjoura D, Lehman A et al.. (2007)
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical.
Blood, 110 (7): 2569-77. [PMID:17440052]